Patient, if not long-suffering, shareholders in Rochester Medical (NASDAQ:ROCM) finally got their vindication on Wednesday, as Bard (NYSE:BCR) stepped up with an all-cash offer for this largely home-care focused urology devices company. Although this deal is not going to radically change the growth outlook for Bard, it is a logical buy-vs-build move that should add long-term value and give the company entry into a market that should be poised for growth in the coming years.
Farewell, And Thanks For The Profits
Rochester Medical announced that it had received and accepted a $262 million all-cash deal from Bard worth $20 per share. That gives Rochester Medical shareholders a 45% premium to Tuesday's close, and the stock hasn't...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|